WARREN, N.J. - Tuesday, 24. January 2023
The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level.
Secondary endpoints measuring the red…